Seizure drug could tame autism irritability in kids
NCT ID NCT07635862
First seen Jun 22, 2026 · Last updated Jun 23, 2026 · Updated 1 time
Summary
This study tests whether ganaxolone, a medicine already used for seizures in a rare genetic disorder, can reduce irritability in autistic children aged 5 to 17. About 66 participants will receive either the drug or a placebo for 12 weeks. The main goal is to see if it improves emotional regulation and quality of life, with a focus on repetitive behaviors as a secondary outcome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTISM SPECTRUM DISORDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
Stanford, California, 94305, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ganaxolone (Ztalmy)
What this could lead to
If it works, this could point toward a new option for managing irritability and repetitive behaviors in autistic children, potentially with fewer side effects than current antipsychotics.
What could go wrong
This is an early phase 2 trial with only 66 participants, so results may not apply to all autistic children. The drug is already approved for seizures in a rare condition, but its effect on autism symptoms is unproven.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.